Last Updated on
People with opioid use disorder are commonly infected with Hepatitis C virus (HCV) and/or HIV. It is important that all providers delivering treatment to individuals with opioid use disorder understand appropriate prevention, screening and treatment strategies of HCV and HIV and specific considerations for people receiving opioid agonist therapy. This includes an understanding of the latest technology used for detection of HCV and HIV, appropriate use of highly effective antiviral therapy, and recognition of potential interactions with methadone, buprenorphine and naltrexone. A strong foundation in understanding HCV and HIV prevention and treatment strategies is important for all providers treating individuals with opioid use disorder.
Click here to view full Webinar information.
View Webinar Slides
Training with CME Credit
Among patients with opioid use disorder,
Be aware of screening and testing strategies for HCV and HIV;
Discuss the natural history and transmission risk of HCV and HIV;
Understand HCV and HIV prevention strategies;
Review current treatment approaches for HCV and HIV and recognize important treatment considerations
American Academy of Addiction Psychiatry is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
American Academy of Addiction Psychiatry designates this enduring material for a maximum of (one) 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Jeanette M. Tetrault, MD FACP | Assistant Professor of Medicine Yale University School of Medicine
Jennifer Edelman, MD, MHS
A follow-up webinar will take place on October 22, 2015 @ 2:00 pm – 3:00 pm ET to further discuss this webinar and allow participants the opportunity to ask questions directly to the experts. Completion of the archived webinar is a pre-requisite for the follow-up webinar. Upon completion of the archived webinar, post test and evaluation, you will receive a link to register for the follow-up webinar.